Barclays PLC Has $2.42 Million Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Barclays PLC lifted its holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 402.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 289,688 shares of the company's stock after acquiring an additional 232,089 shares during the period. Barclays PLC owned 0.54% of Zevra Therapeutics worth $2,416,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of ZVRA. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Zevra Therapeutics in the fourth quarter valued at $94,000. Virtu Financial LLC purchased a new position in Zevra Therapeutics during the third quarter valued at approximately $127,000. Invesco Ltd. grew its position in shares of Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company's stock valued at $153,000 after acquiring an additional 3,007 shares during the period. SG Americas Securities LLC raised its holdings in shares of Zevra Therapeutics by 54.6% during the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company's stock valued at $196,000 after acquiring an additional 8,302 shares during the last quarter. Finally, Corebridge Financial Inc. lifted its stake in shares of Zevra Therapeutics by 16.9% in the fourth quarter. Corebridge Financial Inc. now owns 26,294 shares of the company's stock worth $219,000 after buying an additional 3,801 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors.

Insider Activity at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 61,273 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares in the company, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the completion of the transaction, the chief financial officer now owns 51,361 shares in the company, valued at $403,697.46. This trade represents a 17.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

ZVRA has been the topic of a number of research analyst reports. Citigroup restated an "outperform" rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research report on Thursday, March 13th. JMP Securities set a $18.00 target price on Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Finally, Canaccord Genuity Group lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Zevra Therapeutics currently has a consensus rating of "Buy" and an average target price of $22.29.

Zevra Therapeutics Trading Up 4.7 %

Shares of Zevra Therapeutics stock traded up $0.36 on Friday, reaching $8.00. 597,771 shares of the company were exchanged, compared to its average volume of 618,151. Zevra Therapeutics, Inc. has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The firm has a market capitalization of $437.43 million, a price-to-earnings ratio of -4.06 and a beta of 1.94. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The stock has a fifty day moving average price of $7.50 and a 200-day moving average price of $8.09.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million during the quarter, compared to analyst estimates of $8.93 million. On average, analysts expect that Zevra Therapeutics, Inc. will post -1.95 EPS for the current year.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.